Meeting
2014 ASCO Annual Meeting
Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
Authors
Veronique Dieras
Institut Curie, Paris, France
Veronique Dieras , Thomas Bachelot , Mario Campone , Nicolas Isambert , Florence Joly , Christophe Le Tourneau , Philippe Alexandre Cassier , Emmanuelle Bompas , Pierre Fumoleau , Sabine Noal , Christine Orsini , Marta Jimenez , Diane Charlotte Imbs , Etienne Chatelut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01165385
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2583)
DOI
10.1200/jco.2014.32.15_suppl.2583
Abstract #
2583
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2012 ASCO Annual Meeting
Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
First Author: Herlinde Dumez